Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: US tax policies challenge pharma; J&J’s long-time R&D head to retire; Legend Biotech’s CEO talks about plans; BMS disappointment in ulcerative colitis; and another gene therapy partnership for Takeda.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 15 October 2021, including: US tax policies challenge pharma; Johnson & Johnson’s long-time R&D head to retire; Legend Biotech Corp.’s CEO talks about plans; Bristol Myers Squibb Company disappointment in ulcerative colitis; and another gene therapy partnership for Takeda Pharmaceutical Co. Ltd.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "As Cilta-Cel’s Big Day Approaches, Legend Looks Beyond Myeloma" - Scrip, 8 Oct, 2021.)
(Also see "Bristol's High Profile TYK2 Inhibitor Disappoints In Ulcerative Colitis" - Scrip, 7 Oct, 2021.)
(Also see "Takeda Continues Recent Gene Therapy Partnering Spree With Poseida Pact" - Scrip, 12 Oct, 2021.)